Breaking News

GB Sciences Selects Catalent for Oral Delivery Systems

Will tackle formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GB Sciences has selected Catalent Pharma Solutions to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacture of GB Sciences’ active pharmaceutical ingredients for its Parkinson’s disease therapies. Catalent will conduct a proof of concept study at its Swindon, UK facility to evaluate GB Sciences’ clinical candidates GBS101, GBS102, and GBS103 using Catalent’s Zydis Orally Disintegrating Tablet (ODT) technology. GB Sciences’ APIs for Parkinson’s diseas...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters